logo
logo

Vergent Bioscience, Inc announced it raised $21.5 Million in an initial filing from an offering of $22.1 Million

Vergent Bioscience, Inc announced it raised $21.5 Million in an initial filing from an offering of $22.1 Million

10/04/22, 1:38 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgminneapolis
Money raised
$21.5 million
Industry
biotechnology

Company Info

Company
Vergent Bioscience, Inc.
Location
5810 w 78th st
minneapolis, minnesota, united states
Additional Info
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

Related People